Drug intelligence / Profile preview

Cartijoint Forte

Development stage
Unknown
Lead developer
Fidia Farmaceutici
Modality
Small Molecules
Administration
Oral
01

Overview

Cartijoint Forte is a multi-ingredient dietary supplement developed by Fidia Farmaceutici for the management of joint health and symptoms associated with mild-to-moderate osteoarthritis. It is formulated as a tablet containing glucosamine hydrochloride (415 mg), chondroitin sulfate (400 mg), and BCM-95 bio-curcumin (50 mg) derived from *Curcuma longa*. The supplement acts as a chondroprotective agent by providing precursors for proteoglycan synthesis, limiting the degradation of articular cartilage, and reducing joint inflammation through the anti-inflammatory properties of curcuminoids. Clinical pilot studies have demonstrated its efficacy in improving pain at rest, pain during movement, and functional capacity (WOMAC scores) in patients with knee osteoarthritis, although it may be less effective than hyaluronic acid-based supplements in certain pain metrics.

Brand names
Cartijoint Forte
Other names
Cartijoint Forte
02

Targets

FMOD (Fibromodulin / FMOD)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Cartijoint Forte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cartijoint Forte.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call